Stereoelectronic properties of spiroquinazolinones in differential PDE7 inhibitory activity

A detailed computational study on a series of spiroquinazolinones showing phosphodiesterase 7 (PDE7) inhibitory activity was performed to understand the binding mode and the role of stereoelectronic properties in binding. Our docking studies reproduced the essential hydrogen bonding and hydrophobic interactions for inhibitors of this class of enzymes. The N1 proton of the quinazolinone scaffold was involved in H‐bonding to an amide side chain of the conserved glutamine residue in the active site. The central bicyclic ring of the molecules showed hydrophobic and π‐stacking interactions with hydrophobic and aromatic amino acid residues, respectively, present in the PDE7 active site. The docked conformations were optimized with density functional theory (DFT) and DFT electronic properties were calculated. Comparison of molecular electrostatic potential (MEP) plots of inhibitors with the active site of PDE7 suggested that the electronic distribution in the molecules is as important as steric factors for binding of the molecules to the receptor. The hydrogen bonding ability and nucleophilic nature of N1 appeared to be important for governing the interaction with PDE7. For less active inhibitors (pIC50 < 6.5), the MEP maximum at N1 of the spiroquinazolinone ring was high or low based on the electronic properties of the substituents. All the more active molecules (pIC50 > 6.5) had MEP highest at N3, not N1. Efficient binding of these inhibitors may need some rearrangement of side chains of active‐site residues, especially Asn365. This computational modeling study should aid in design of new molecules in this class with improved PDE7 inhibition. © 2008 Wiley Periodicals, Inc. J Comput Chem 2008

[1]  K. Chung,et al.  Phosphodiesterase inhibitors in airways disease , 2006 .

[2]  A. Becke A New Mixing of Hartree-Fock and Local Density-Functional Theories , 1993 .

[3]  H. Ke,et al.  Multiple Elements Jointly Determine Inhibitor Selectivity of Cyclic Nucleotide Phosphodiesterases 4 and 7* , 2005, Journal of Biological Chemistry.

[4]  H. Dyke,et al.  Synthesis and structure-activity relationships of guanine analogues as phosphodiesterase 7 (PDE7) inhibitors. , 2001, Bioorganic & medicinal chemistry letters.

[5]  Y. Martin,et al.  Do structurally similar molecules have similar biological activity? , 2002, Journal of medicinal chemistry.

[6]  J. Karle,et al.  Stereoelectronic properties of antimalarial artemisinin analogues in relation to neurotoxicity. , 1999, Chemical research in toxicology.

[7]  A. Karpfen,et al.  Molecular Geometries and Vibrational Spectra of Phenol, Benzaldehyde, and Salicylaldehyde: Experimental versus Quantum Chemical Data , 1997 .

[8]  Electrostatics in chemistry , 1999 .

[9]  Thomas Lengauer,et al.  A fast flexible docking method using an incremental construction algorithm. , 1996, Journal of molecular biology.

[10]  Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: Advances in the development of specific phosphodiesterase inhibitors , 2005, Medicinal research reviews.

[11]  J. Palacios,et al.  Differential distribution of cAMP‐specific phosphodiesterase 7A mRNA in rat brain and peripheral organs , 2001, Synapse.

[12]  P. Berna,et al.  Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 2: Optimization of 5,8-disubstituted derivatives. , 2004, Bioorganic & medicinal chemistry letters.

[13]  J. Y. Roberge,et al.  Identification of purine inhibitors of phosphodiesterase 7 (PDE7). , 2004, Bioorganic & medicinal chemistry letters.

[14]  P. Soulard,et al.  Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies. , 2004, Bioorganic & medicinal chemistry letters.

[15]  É. Chevalier,et al.  PDE7 Inhibitors: Chemistry and Potential Therapeutic Utilites , 2005 .

[16]  Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[17]  T. Halgren Merck molecular force field. II. MMFF94 van der Waals and electrostatic parameters for intermolecular interactions , 1996 .

[18]  Parr,et al.  Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density. , 1988, Physical review. B, Condensed matter.

[19]  M. Pruniaux,et al.  Phosphodiesterase (PDE) 7 in inflammatory cells from patients with asthma and COPD. , 2007, Pulmonary pharmacology & therapeutics.

[20]  D. Underwood,et al.  Effects of heterocyclic aromatic substituents on binding affinities at two distinct sites of somatostatin receptors. Correlation with the electrostatic potential of the substituents. , 2003, Journal of medicinal chemistry.

[21]  F. J. Luque,et al.  Generalization of the Molecular Electrostatic Potential for the Study of Noncovalent interactions , 1996 .

[22]  Thomas A. Halgren,et al.  Merck molecular force field. III. Molecular geometries and vibrational frequencies for MMFF94 , 1996, J. Comput. Chem..

[23]  David G. Brown,et al.  Design of second generation phosphodiesterase 5 inhibitors. , 2007, Current topics in medicinal chemistry.

[24]  T. Halgren MMFF VII. Characterization of MMFF94, MMFF94s, and other widely available force fields for conformational energies and for intermolecular‐interaction energies and geometries , 1999, Journal of computational chemistry.

[25]  T. Halgren Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94 , 1996, J. Comput. Chem..

[26]  J. Murray,et al.  Molecular electrostatic potentials : concepts and applications , 1996 .

[27]  Susan J. Smith,et al.  Phosphodiesterase 7 (PDE7) as a therapeutic target , 2006 .

[28]  R. Cantor,et al.  Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response , 2006, Proceedings of the National Academy of Sciences.

[29]  K. Wanner,et al.  Methods and Principles in Medicinal Chemistry , 2007 .

[30]  B. Pullman,et al.  Molecular electrostatic potential of the nucleic acids , 1981, Quarterly Reviews of Biophysics.

[31]  David T Manallack,et al.  The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases. , 2005, Journal of medicinal chemistry.

[32]  Adriaan P. IJzerman,et al.  Relative binding orientations of adenosine A1 receptor ligands — A test case for Distributed Multipole Analysis in medicinal chemistry , 1995, J. Comput. Aided Mol. Des..

[33]  Kam Y. J. Zhang,et al.  A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases. , 2004, Molecular cell.

[34]  A. Becke Density-functional thermochemistry. III. The role of exact exchange , 1993 .

[35]  F. Menniti,et al.  Phosphodiesterases in the CNS: targets for drug development , 2006, Nature Reviews Drug Discovery.

[36]  J. Karle,et al.  Molecular electronic properties of a series of 4-quinolinecarbinolamines define antimalarial activity profile. , 1996, Journal of medicinal chemistry.

[37]  T. Sasaki,et al.  Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors , 2002, Clinical and experimental immunology.

[38]  Maria Kontoyianni,et al.  Evaluation of docking performance: comparative data on docking algorithms. , 2004, Journal of medicinal chemistry.

[39]  S. Sj,et al.  Phosphodiesterase 7A: a new therapeutic target for alleviating chronic inflammation? , 2006 .

[40]  P. Berna,et al.  Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 2: metabolism-directed optimization studies towards orally bioavailable derivatives. , 2004, Bioorganic & medicinal chemistry letters.

[41]  Anthony K. Grafton,et al.  A COMPARISON OF THE PROPERTIES OF VARIOUS FUSED-RING QUINONES AND THEIR RADICAL ANIONS USING HARTREE-FOCK AND HYBRID HARTREE-FOCK/DENSITY FUNCTIONAL M ETHODS , 1997 .

[42]  Steven D. Schwartz,et al.  Molecular Electrostatic Potential Analysis for Enzymatic Substrates, Competitive Inhibitors, and Transition-State Inhibitors , 1996 .

[43]  Didier Rognan,et al.  Comparative evaluation of eight docking tools for docking and virtual screening accuracy , 2004, Proteins.

[44]  Y. Jeon,et al.  Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development , 2005, Cellular and Molecular Life Sciences CMLS.

[45]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[46]  T. K. Chandrashekar,et al.  22pi smaragdyrin molecular conjugates with aromatic phenylacetylenes and ferrocenes: Syntheses, electrochemical, and photonic properties. , 2006, Journal of the American Chemical Society.

[47]  Y. Shimizu,et al.  Amelioration of collagen-induced arthritis in mice by a novel phosphodiesterase 7 and 4 dual inhibitor, YM-393059. , 2007, European journal of pharmacology.

[48]  J. Beavo,et al.  Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use , 2006, Pharmacological Reviews.